2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2020
Primary melanotic tumors of the nervous system: a consecutive case series
Grosshans H, Huttner A, Piepmeier J, Kaulen L, Fulbright R, Baehring J, Karschnia P. Primary melanotic tumors of the nervous system: a consecutive case series. European Journal Of Neurology 2020, 27: 2303-2307. PMID: 32654331, DOI: 10.1111/ene.14437.Peer-Reviewed Original ResearchConceptsPrimary melanotic tumorsNervous systemRelapsed diseaseClinical presentationMelanotic lesionsFavorable outcomeRadiation therapyPre-contrast T1-weighted imagingRelative incidenceMelanotic tumorsHomogenous contrast enhancementYale Cancer CenterAggressive surgical treatmentConsecutive case seriesPsammomatous melanotic schwannomaNervous system tumorsT1-weighted imagingT2-weighted imagingTumor mass effectMagnetic resonance imagingMelanin-containing cellsS100 positivitySurgical resectionSurgical treatmentTumor Registry
2019
Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience
Karschnia P, Barbiero FJ, Schwaiblmair MH, Kaulen LD, Piepmeier JM, Huttner AJ, Becker KP, Fulbright RK, Baehring JM. Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience. Neuro-Oncology Practice 2019, 7: 118-126. PMID: 32257290, PMCID: PMC7104875, DOI: 10.1093/nop/npz020.Peer-Reviewed Original ResearchLeptomeningeal disseminationRare complicationCNS tumorsInitial tumor diagnosisMedian overall survivalYale Cancer CenterPredictors of outcomeMean time intervalAggressive treatmentOverall survivalSystemic therapyConsecutive patientsSystemic treatmentTumor depositsClinical presentationCancer CenterHistopathological diagnosisHistological entityClinical signsTimely diagnosisNeuro-oncologyTumor spectrumEarly symptomsVariable enhancementRelative incidence
2018
Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.
Lester-Coll N, Supko J, Kluytenaar J, Pavlik K, Yu J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Contessa J, Ramani R, Lampert R, Yao X, Bindra R. Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. Journal Of Clinical Oncology 2018, 36: e14046-e14046. DOI: 10.1200/jco.2018.36.15_suppl.e14046.Peer-Reviewed Original ResearchLeptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159)
Karschnia P, Barbiero F, Schwaiblmair M, Piepmeier J, Huttner A, Becker K, Fulbright R, Baehring J. Leptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p6.159.Peer-Reviewed Original Research
2016
Mibefradil Dihydrochloride With Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial
Lester-Coll N, Kluytenaar J, Pavlik K, Yu J, Contessa J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Ramani R, Lampert R, Yao X, Bindra R. Mibefradil Dihydrochloride With Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s93. DOI: 10.1016/j.ijrobp.2016.06.233.Peer-Reviewed Original ResearchRecurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrión-Grant G, Mishra-Gorur K, Durán D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Günel JM, Bilgüvar K, Yasuno K, Young RA, Günel M. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics 2016, 48: 1253-1259. PMID: 27548314, PMCID: PMC5114141, DOI: 10.1038/ng.3651.Peer-Reviewed Original ResearchCatalytic DomainChromosomes, Human, Pair 22Cohort StudiesDNA Mutational AnalysisEnhancer Elements, GeneticExomeGene Expression Regulation, NeoplasticGenotypeHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMeningeal NeoplasmsMeningiomaMutationNeurofibromin 2RNA Polymerase IITumor Necrosis Factor Receptor-Associated Peptides and ProteinsIncreased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancy
2015
ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL
Lester-Coll N, Kluytenaar J, Pavlik K, Yu J, Contessa J, Moliterno J, Piepmeier J, Becker K, Baehring J, Huttner A, Vortmeyer A, Ramani R, Lampert R, Yao X, Bindra R. ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL. Neuro-Oncology 2015, 17: v13-v13. PMCID: PMC4638537, DOI: 10.1093/neuonc/nov205.15.Peer-Reviewed Original Research
2014
Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance
Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. Journal Of Neuro-Oncology 2014, 121: 441-449. PMID: 25403507, PMCID: PMC4323763, DOI: 10.1007/s11060-014-1658-0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBrain NeoplasmsConvectionDrug Delivery SystemsFerric CompoundsGlioblastomaHumansImage Processing, Computer-AssistedLactic AcidMagnetic Resonance ImagingNanoparticlesNeuroimagingPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRatsRats, Sprague-DawleyConceptsBrain-penetrating nanoparticlesSuperparamagnetic iron oxideEfficient deliveryDrug-loaded nanoparticlesDistribution of nanoparticlesTransverse relaxivityPLGA nanoparticlesNanoparticlesConvection-enhanced deliveryDelivery platformFuture clinical applicationsUniversal tumor recurrenceClinical translationSignal attenuationDetection modalitiesIron oxideSame morphologyParticle distributionDeliveryGroundbreaking approachClinical applicationRelevant volumesRelaxivityTreatment of GBMOxide
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original ResearchClinical Presentation in Diffuse Low-Grade Gliomas
Torres-Reveron J, Piepmeier J, Becker K. Clinical Presentation in Diffuse Low-Grade Gliomas. 2013, 179-188. DOI: 10.1007/978-1-4471-2213-5_12.Peer-Reviewed Original ResearchDiffuse low-grade gliomasLow-grade gliomasCommon presenting symptomHigh-grade lesionsPrimary brain tumorsStandard imaging modalityPresenting symptomHistopathological findingsClinical presentationTumor sizeNeurological syndromeAnaplastic transformationBrain tumorsMultimodal evaluationConventional imaging technologiesImaging modalitiesActive investigationTumorsGliomasNew advancesSeizuresSyndromeLesionsSymptomsGenomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and Proteins
2012
Low-Grade Gliomas When and How to Treat
Omay SB, Piepmeier JM, Knisely JP. Low-Grade Gliomas When and How to Treat. Hematology/Oncology Clinics Of North America 2012, 26: 797-809. PMID: 22794284, DOI: 10.1016/j.hoc.2012.05.001.Peer-Reviewed Original ResearchConceptsSurgical resectionLow-grade gliomasPatient-specific variablesSame imaging techniqueRadiotherapeutic managementUncommon tumorClinical trialsOperative techniqueHistopathologic characterizationGrade gliomasOptimal managementAdditional studiesGliomasResectionAdequate samplesImaging techniquesPatientsPrognosisManagementTumorsTrialsRole of Neurosurgery and Radiation Therapy in the Management of Brain Tumors
Patel TR, Yu JB, Piepmeier JM. Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors. Hematology/Oncology Clinics Of North America 2012, 26: 757-777. PMID: 22794282, DOI: 10.1016/j.hoc.2012.04.001.Peer-Reviewed Original ResearchGiant myofibroma of the orbit in an adult male.
Servat JJ, Williamson JE, Piepmeier J, Sinard J, Bernardino CR. Giant myofibroma of the orbit in an adult male. Orbit (Amsterdam, Netherlands) 2012, 31: 21-3. PMID: 22007896, DOI: 10.3109/01676830.2011.605501.Peer-Reviewed Original ResearchNeurosurgical Approach
Moliterno JA, Patel TR, Piepmeier JM. Neurosurgical Approach. The Cancer Journal 2012, 18: 20-25. PMID: 22290253, DOI: 10.1097/ppo.0b013e3183243f6e3.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingTumor cellsResonance imagingAggressive surgical resectionAggressive tumor removalFunctional brain tissueFrequency of seizuresExtent of resectionGoal of surgeryInfiltrative tumor cellsPreferred initial stepFunctional magnetic resonance imagingProliferative tumor cellsAdjuvant therapyAggressive resectionSurgical resectionTumors recurCritical cortical regionsNeurologic impairmentTumor burdenProspective studyTumor resectionTumor removalInfiltrative tumorsMalignant gliomasChapter 27 Surgical Approaches to Lateral and Third Ventricular Tumors
Patel T, Gould G, Baehring J, Piepmeier J. Chapter 27 Surgical Approaches to Lateral and Third Ventricular Tumors. 2012, 330-338. DOI: 10.1016/b978-1-4160-6839-6.10027-9.Peer-Reviewed Original Research
2011
Polymeric nanoparticles for drug delivery to the central nervous system
Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Advanced Drug Delivery Reviews 2011, 64: 701-705. PMID: 22210134, PMCID: PMC3323692, DOI: 10.1016/j.addr.2011.12.006.Peer-Reviewed Original ResearchBiodegradable poly(amine-co-ester) terpolymers for targeted gene delivery
Zhou J, Liu J, Cheng CJ, Patel TR, Weller CE, Piepmeier JM, Jiang Z, Saltzman WM. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nature Materials 2011, 11: 82-90. PMID: 22138789, PMCID: PMC4180913, DOI: 10.1038/nmat3187.Peer-Reviewed Original ResearchConceptsGene deliveryNon-viral gene deliveryEfficient gene deliveryGene delivery abilityTargeted gene deliveryHighest molecular weight terpolymerDelivery abilityTargeted deliveryLipofectamine 2000Dialkyl diesterVivo applicationsPolycationic vectorsSpecific ring sizesTRAIL geneHigh efficiencyCharge densityLow charge densityDeliveryPolyethylenimineMinimal toxicityEfficiencyHydrophobicityLactone contentDensityApplications